The potential of simultaneously targeting ER, PI3K/mTOR, and CDK4/6 signaling de novo was evaluated in three ER+/HER2− breast cancer xenograft models representing diverse molecular backgrounds of PI3K/mTOR pathway activation. Here, CDK4 is linked to breast carcinoma.